Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Dilmapimod
Cat. No.:
OB0225LY-0435
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Dilmapimod is a small molecule p38 MAPK inhibitor that shows potential in inflammation and cancer research.
Synonym:
SB-681323; GW 681323; 444606-18-2; 8-(2,6-Difluorophenyl)-2-((1,3-dihydroxypropan-2-yl)amino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7(8H)-one; SB681323; 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one
CAS No.:
444606-18-2
Compound CID:
10297982
Formula:
C23H19F3N4O3
Formula Weight:
456.42
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Dilmapimod can be used for cell signaling pathway studies or play an important role in inflammatory disease modeling studies.
Library Information
Targets:
Kinases
Receptors:
p38 MAPK
Pathways:
MAPK; Autophagy
Plate Number:
AOCL-6
Plate Location:
f2
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
125 mg/mL; 273.87 mM
